Anticoagulant: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
imported>Robert Badgett
No edit summary
Line 1: Line 1:
{{subpages}}
{{subpages}}
'''Anticoagulants''' are "agents that prevent blood clotting".<ref name="title">{{cite web |url=http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi?mode=&index=883&field=all&HM=&II=&PA=&form=&input= |title=Anticoagulants |accessdate=2007-12-20 |author=National Library of Medicine |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> They may be used to prevent [[thromboembolism]].
'''Anticoagulants''' are "agents that prevent [[coagulation|blood clotting]]".<ref name="title">{{cite web |url=http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi?mode=&index=883&field=all&HM=&II=&PA=&form=&input= |title=Anticoagulants |accessdate=2007-12-20 |author=National Library of Medicine |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> They may be used to prevent [[embolism and thromboembolism]].
{{editintro}}
{{editintro}}
==Vitamin K antagonists==
==Vitamin K antagonists==
Line 9: Line 9:


==Heparin==
==Heparin==
Details of the usage of heparin are available in [[clinical practice guideline]]s by the [[American College of Chest Physicians]]<ref name="pmid15383472">{{cite journal |author=Hirsh J, Raschke R |title=Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy |journal=Chest |volume=126 |issue=3 Suppl |pages=188S-203S |year=2004 |pmid=15383472 |doi=10.1378/chest.126.3_suppl.188S}}</ref>:
Details of the usage of heparin are available in [[clinical practice guideline]]s by the [[American College of Chest Physicians]]<ref name="pmid15383472">{{cite journal |author=Hirsh J, Raschke R |title=Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy |journal=Chest |volume=126 |issue=3 Suppl |pages=188S-203S |year=2004 |pmid=15383472 |doi=10.1378/chest.126.3_suppl.188S|url=http://www.chestjournal.org/cgi/content/full/126/3_suppl/204S}}</ref>:
* [http://www.chestjournal.org/cgi/content/full/126/3_suppl/188S/T4 Non-weight based heparin dose adjustment]
* [http://www.chestjournal.org/cgi/content/full/126/3_suppl/188S/T4 Non-weight based heparin dose adjustment]
* [http://www.chestjournal.org/cgi/content/full/126/3_suppl/188S/T5 Weight-based heparin dose adjustment]
* [http://www.chestjournal.org/cgi/content/full/126/3_suppl/188S/T5 Weight-based heparin dose adjustment]

Revision as of 15:07, 24 January 2008

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Anticoagulants are "agents that prevent blood clotting".[1] They may be used to prevent embolism and thromboembolism.

[edit intro]

Vitamin K antagonists

Warfarin

For more information, see: warfarin.


Warfarin is a commonly used oral anticoagulant that interferes with the Vitamin K dependent coagulation co-factors.

Heparin

Details of the usage of heparin are available in clinical practice guidelines by the American College of Chest Physicians[2]:

Direct thrombin inhibitors

Direct thrombin inhibitors bind directly to thrombin.[3]

Factor Xa inhibitors

Idraparinux is a synthetic derivative of heparin that has a long half life that allows once-weekly dosage. A randomized controlled trial compared idraparinux to warfarin and found that idraparinux is equivalent for deep venous thrombosis but is inferior for pulmonary embolism.[4]

References

  1. National Library of Medicine. Anticoagulants. Retrieved on 2007-12-20.
  2. Hirsh J, Raschke R (2004). "Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy". Chest 126 (3 Suppl): 188S-203S. DOI:10.1378/chest.126.3_suppl.188S. PMID 15383472. Research Blogging.
  3. Di Nisio M, Middeldorp S, Büller HR (2005). "Direct thrombin inhibitors". N. Engl. J. Med. 353 (10): 1028–40. DOI:10.1056/NEJMra044440. PMID 16148288. Research Blogging.
  4. Buller HR, Cohen AT, Davidson B, et al (2007). "Idraparinux versus standard therapy for venous thromboembolic disease". N. Engl. J. Med. 357 (11): 1094–104. DOI:10.1056/NEJMoa064247. PMID 17855670. Research Blogging.

See also

External links

The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines